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a  b  s  t  r  a  c  t
CA19.9  antigen  is  a glycoprotein  present  in  human  serum  and  found  elevated  in  various  diseases.  It is
intensively  studied  since  long  time  as  a potential  marker  for managing  cancers  of the  gastrointestinal  tract,
but  its  reliability  is  widely  accepted  only  for  pancreatic  cancers.  Here,  we  focused  on the  tetrasaccharide
epitope  (NeuAc2-3Gal1-3[Fuc1-4]GlcNAc)  sialyl-Lewis  a  studying  the  biosynthesis,  expression,  and
secretion in  colon  cancers  and  related  cancer  cell  lines.  We  found  that  the  1,3 galactosyltransferase
3Gal-T5,  responsible  for  sialyl-Lewis  a  synthesis,  is  dramatically  reduced  in colon  adenocarcinomas,
in  terms  of both  transcript  and  enzyme  activity  levels.  Moreover,  no  or very  faint antigen  is  detectable
in colon  cancer  homogenates,  by  dot-blot  or enzyme  immunoassay,  while  it is commonly  evident  in
sera from  different  patients.  In  cancer  cell  lines  synthesizing  CA19.9,  the  amount  of  antigen  secreted  is
proportional  to  that  expressed  on the  cell  surface,  and  depends  on  appreciable  levels  of 3Gal-T5,  which
appear  much  higher  than  those  measured  in colon  cancer  specimens.  Since  colon  cancers  appear  unable
to synthesize  relevant  amount  of  CA19.9,  we  suggest  that  the antigen  circulating  in the  serum  of  colon
cancer  patients  may  have  a different  and  more  complex  origin  than  expected  so  far.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Sialyl-Lewis a is the tetrasaccharide epitope (NeuAc2-3Gal1-
3[Fuc1-4]GlcNAc)1 characterizing the CA19.9 antigen (Magnani
et al., 1983; Yue et al., 2011a)  present in human serum and found
elevated in various diseases (Mann et al., 2000) including cancers
of the digestive tract, as pancreas (Ballehaninna and Chamberlain,
2012), bile ducts (Kikkawa et al., 2012), stomach (Kim et al., 2011),
and colon (Yamashita and Watanabe, 2009). At present, CA19.9
is recommended by medical societies and study groups for man-
aging cancers of the pancreas but not of the colon (Duffy et al.,
2003, 2007, 2010; Locker et al., 2006), but is still widely used
in clinical practice, trials, and studies concerning colorectal can-
cer diagnosis, prognosis, surveillance, and response to therapy (de
Haas et al., 2010; Byström et al., 2012; Lin et al., 2012). The exist-
ence of such controversial issues and the ﬁnding of high CA19.9
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1 The abbreviations used are: sLea, sialyl-Lewis a, NeuAc2-3Gal1-3[Fuc1-
4]GlcNAc; sLex, sialyl-Lewis x, NeuAc2-3Gal1-4[Fuc1-3]GlcNAc; Gal-T, galacto-
syltransferase; Fuc-TIII, 1,3/1,4fucosyltransferase type III (product of FUT3 gene);
EIA, enzyme immunoassay; CEA, carcinoembryonic antigen.
in the serum of patients suffering non-malignant diseases (van
der Veek et al., 2011), open questions about the biology of such
molecule and the rationale of the use as a reliable marker. Lit-
tle is known about CA19.9 structure, synthesis and secretion in
the different tissues, and nothing about the origin of that circu-
lating in health individuals. Recently, it was  found that multiple
proteins carry the epitope in pancreatic cancer and none appears
responsible for cancer up-regulation (Yue et al., 2011b). This may
suggest that the synthesis of the carbohydrate epitope is limiting
in determining the serum levels. In fact, Narimatsu et al. (1998)
reported that FUT3 (Lewis gene) dosage affects CA19.9 positively,
while FUT2 (Secretor type 1,2 fucosyltransferase, competing for
the synthesis) negatively. In colon cancer, however, among speciﬁc
glycosyltransferases required for epitope biosynthesis (fucosyl-
transferase Fuc-TIII, 2,3 sialyltransferases ST3GalIV or ST3GalIII,
and 1,3 galactosyltransferase 3Gal-T5) none is up regulated (Ito
et al., 1997; Kudo et al., 1998; Misonou et al., 2009; Dall’Olio et al.,
2012). In particular, 3Gal-T5 transcript is expressed in normal
colon mucosa but dramatically down-regulated in adenocarcino-
mas  (Salvini et al., 2001; Isshiki et al., 2003; Caretti et al., 2012),
conﬁrming the observation that 1,3Gal-T activity is impaired in
colon cancers (Seko et al., 1996; Misonou et al., 2009), where type
2 chain oligosaccharides (based on Gal1-4GlcNAc sequence) pre-
dominate over type 1 chain (based on Gal1-3GlcNAc sequence)
in various glycoconjugates (Misonou et al., 2009). On this light, the
1357-2725/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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concept that CA19.9 is a cancer-associated antigen in human colon
appears paradoxical and deserves more investigations.
To address this issue we measured the levels of 3Gal-T5 tran-
script and 1,3Gal-T activity in bioptic samples pairs from colon
adenocarcinomas and surrounding normal mucosa, and deter-
mined the amount of sLea antigen expressed in the tissues. We also
evaluated in cultured cell lines expressing the antigen their ability
to secrete it in the medium. We  then compared the obtained data
with the amount of antigen detected in control and patient sera.
2. Materials and methods
2.1. Cell cultures
COLO-205, HCT-15, CACO-2, HT-29 (from human colon adeno-
carcinomas), and MKN-45 (from human gastric cancer) cells were
cultured as previously described (Valli et al., 1998; Salvini et al.,
2001). MKN-45 cells expressing Fuc-TIII, named MKN-45-FT, and
human pancreatic adenocarcinoma cells BxPC3 and Panc-1, were
obtained and cultured as reported (Mare and Trinchera, 2004).
CACO-2 cells differentiated in culture were obtained according to
the procedure described (Isshiki et al., 2003).
2.2. Preparation of human colon samples and cultured cells for
analytical procedures
Human bioptic specimens were collected at surgery, immedi-
ately frozen in dry ice and placed in liquid nitrogen until used,
as previously reported (Salvini et al., 2001; Caretti et al., 2012).
They originated from different parts of the large intestine, includ-
ing the rectum (samples 3 and 6). Cancers were staged from B2
to C2 (Dukes’) and graded from moderately to poorly differen-
tiated. The health mucosa surrounding the cancer lesion in the
same surgical resection was referred to as the normal mucosa.
For RNA extraction, 1–2 mm3 of frozen material was cut, placed
in 0.3 ml  of lysis buffer (Ambion RNAqueous minikit, Invitrogen),
homogenated with a rotary homogenizer, and processed for total
RNA extraction and DNA removal according to the manufacturer’s
recommendations. For biochemical analysis, 2–3 mm3 of frozen
material was cut, carefully rinsed twice in 0.5 ml  of ice-cold phos-
phate buffered saline, placed in 0.5 ml  of 0.1 M Tris/HCl buffer, pH
7.5, and homogenated with a rotary homogenizer. An aliquot of the
homogenates was diluted to different protein concentrations and
used for dot-blots, another aliquot was made 0.5 mg/ml  Triton X-
100 and used as the enzyme source for 1,3Gal-T in vitro assay, and
a third aliquot was lysated for EIA according to a published proce-
dure (Baeckström et al., 1991). Cultured cells were harvested and
freshly processed for ﬂow cytometry as reported (Bardoni et al.,
1999; Salvini et al., 2001). For dot-blot, EIA, and enzyme assay, cell
pellets were treated as described for bioptic samples but vortexing
instead of using the rotary homogenizer.
2.3. RNA analysis
For transcript quantiﬁcation, competitive RT-PCR was per-
formed essentially as previously reported (Trinchera et al., 2011;
Caretti et al., 2012). First strand cDNA was prepared for samples
and controls in the presence, or omitting, the reverse transcriptase,
respectively, and reactions incubated under reported conditions. It
was ampliﬁed (25 l reaction volume) in the presence of 10 fg of
competitor for 35 cycles (3Gal-T5), or 10 pg of competitor for 25
cycles (-actin), under reported conditions. No ampliﬁcation was
detected when the control reactions were used as template. Human
-actin and 3Gal-T5 competitors, and oligonucleotide primers,
were those already described (Salvini et al., 2001). Fuc-TIII tran-
script was quantitated exactly as reported (Trinchera et al., 2011).
2.4. Enzyme assay
1,3Gal-T activity was  determined in the reported reaction mix-
ture (Salvini et al., 2001), using 0.6 M GlcNAc as acceptor, in the
presence of cell or tissue homogenates at various protein con-
centrations: 0.5–4.0 mg/ml  for cell lines and clones, 0.5–2.0 mg/ml
for normal colon mucosa, and 5.0–10 mg/ml  for colon cancers.
Incubations were done at 37 ◦C for 120 (cancers) or 60 min  (all
others). At the end of incubation, reaction products were assayed
by Dowex chromatography and characterized according to pre-
viously reported protocols (Valli et al., 1998). In all cases the
reaction product was found to be a disaccharide sensitive to
1,3galactosidase, as expected. In fact, GlcNAc is not used as
acceptor by 1,4galactosyltransferases under the reported assay
conditions (Valli et al., 1998; Bardoni et al., 1999). One unit of
1,3Gal-T activity corresponds to one nanomole of transferred Gal
per mg  of protein homogenate per hour.
2.5. sLea detection
Detection of sLea by immunoﬂuorescence and ﬂow cytometry
was performed as previously reported (Salvini et al., 2001). For dot-
blots, aliquots from homogenates, sera, bile, or culture media were
applied to the membrane by vacuum aspiration. Serial dilutions
of samples were performed in preliminary experiments to set the
optimal protein concentrations and amounts needed for detection.
Blotting membranes were washed, blocked, stained with primary
and peroxidase-labeled secondary antibodies, and visualized by
enhanced chemiluminescence as reported for western-blot (Caretti
et al., 2012). Monoclonal anti-sLea (from hybridoma 1116-NS-19-9)
antibody was prepared as reported (Bardoni et al., 1999). Quantiﬁ-
cation of CA19.9 in serum and bile samples, in culture media, or
in tissue and cell lysates was performed by EIA with an automated
analytical system (Cobas Core II, Roche Diagnostics) equipped with
dedicated reagents, according to the instructions of the manufac-
turer.
3. Results
3.1. ˇ1,3Gal-T activity, ˇ3Gal-T5 transcript levels, and sLea
expression in normal colon mucosa and adenocarcinomas.
To evaluate the actual ability of colon tissues to synthesize large
amounts of sLea, we  determined 3Gal-T5 transcript and activity
in 9 sample pairs from patient biopsies, each representing colon
adenocarcinomas and surrounding normal mucosa. Serum levels
of CA19.9 were 115, 84.6, and 19.2 U/ml in patients 9, 8, and 4,
respectively (normal range <37 U/ml), and not available in the oth-
ers. Fuc-TIII transcript was  found to be heterogeneously expressed
in all samples (not shown), as expected (Ito et al., 1997; Salvini et al.,
2001; Trinchera et al., 2011).
The amount of 3Gal-T5 transcript expressed in normal colon
mucosa is high but variable, ranging from 3 to 20 fg/pg of -actin,
and the enzyme activity ranges from 22 to 120 U. In cancer sam-
ples, 1,3Gal-T activity closely follows transcript down-regulation
(Fig. 1, panel A, note the different scales used). The calculated reduc-
tion is 36.2-folds on average, ranging from a minimum of 6.2-folds
in sample 6 to a maximum of 68-folds in sample 9. Interestingly, in
a single adenocarcinoma case (sample 5) where the transcript level
is relatively maintained (0.9 fg/pg of -actin) the enzyme activity
reaches the value of 13.2 U, while it is lower than 4 U in all other
samples. This data indicate that 3Gal-T5 down-regulation in colon
cancers leads to extremely low values of enzyme activity.
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Fig. 1. Expression of 3Gal-T5 and sLea in colon samples from cancer patients. Colon
adenocarcinoma and surrounding normal mucosa samples were collected at surgery
and  immediately frozen. The frozen material was  cut in aliquots that were processed
for  analysis as described under Section 2. (A) 3Gal-T5 transcript (full bars) was
quantitated by competitive RT-PCR starting from RNA extracted from an aliquot of
frozen samples, and 1,3Gal-T activity (empty bars) was  determined by in vitro assay
using homogenates prepared from a second aliquot of the frozen samples. Results
are the mean ± standard deviation for three determinations. Note the different scales
used. (B) sLea was  determined by immunostaining of dot-blots prepared with two
amounts of sample homogenates brought to the same ﬁnal volume, using anti-sLea
monoclonal antibody followed by peroxidase-labeled secondary antibody. (C) Dif-
ferent dilutions of the homogenates prepared from two cell lines expressing the
antigen were blotted and stained for reference under identical conditions. Labels
show the actual amount of sample protein blotted.
To directly evaluate the synthesis of sLea in the tissues, sample
homogenates were analyzed through immunostaining of dot-blots.
Surprisingly, under conditions used for detection in cell lines, sLea
is undetectable in both normal colon mucosa and adenocarcinomas
(Fig. 1, panels B and C). Using much more protein in the blots, sLea
is detected in many normal mucosa specimens and faintly in few
cancers, but remains undetectable in others. To better assess the
actual amount of CA19.9 expressed in colon tissues with respect to
cell lines, we measured CA19.9 by EIA in tissue and cell lysates. Such
assay linearly detects CA19.9 in COLO-205 and BxPC3 lysates start-
ing from 5.0 and 10.0 g/ml of cell protein, respectively, while none
is detected using up to 40.0 g/ml of protein lysate from HCT-15, a
cell line known to lack sLea (Fig. 2, lower panel). Using 20.0 g/ml
of protein from colon tissue lysates, CA19.9 is detected at very low
levels in one adenocarcinoma and one normal mucosa sample, and
remains undistinguishable from the background (value detected
in HCT-15 cells) in all other samples (Fig. 2, upper panel). These
ﬁndings demonstrate that no accumulation of sLea occurs in colon
adenocarcinomas.
Fig. 2. Detection of CA19.9 by EIA in lysates from colon biopsies and cultured cell
lines. Cultured cells and colon biopsies were processed for analysis as described
under Section 2. Lower panel, serial dilutions of cell lysates were assayed by EIA.
Upper panel, lysates from the indicated cell lines and from colon biopsies (numbered
as  in Fig. 1) were diluted to a protein concentration of 20 g/ml and assayed by EIA.
Results are the mean ± standard deviation for three determinations.
3.2. Expression and secretion of sLea in cultured cell lines
As a model for studying sLea secretion, we evaluated in cul-
tured cell lines the relationship between sLea secreted in the
culture medium and expressed on the cell surface, since cancer
cell lines secrete mucin-type glycoproteins carrying the epitope
(Baeckström et al., 1991, 1995). To this purpose, a set of cancer cell
lines from the digestive tract expressing different amount of anti-
gens were selected in preliminary experiments. They were plated at
the same density and cultured for 48 h. The amount of sLea present
on the surface was  then quantitated by immunoﬂuorescence and
ﬂow cytometry, while that accumulated in the culture medium
was detected by dot-blot immunostaining and quantitated by EIA
(Fig. 3). Among colon adenocarcinoma cell lines, COLO-205 cells,
expressing very much sLea on the surface, secrete large amount of
antigen in the medium, while CACO-2 and HT-29, expressing low
amount of sLea on the surface, secrete minimal amount of antigen,
as detected by both dot-blot immunostaining and EIA. Moreover, all
cell lines lacking expression on the surface, as HCT-15, Panc-1, and
MKN-45, do not secrete detectable antigen at all. In addition, CACO-
2 cells differentiated in culture and expressing about three times
more 1,3Gal-T activity than undifferentiated cells, also express
more sLea on the surface and secrete more sLea in the medium. On
the other side, BxPC3 cells (from pancreas) expressing intermedi-
ate amount of sLea on the surface, and MKN-45-FT (from stomach),
a recombinant clone forced to express sLea on the surface through
over-expression of Fuc-TIII, secrete a moderate amount of anti-
gen in the medium as detected by dot-blot immunostaining, but
EIA detects much more antigen in the culture medium of BxPC3.
Altogether these data indicate that secretion of CA19.9 antigen in
cancer cell lines does not occur in the absence of concurrent expres-
sion on the surface, and only cells expressing 3Gal-T5 are able to
secrete relevant amounts of antigen. Interestingly, there is a very
good correlation between the amounts of antigen expressed on
the surface and secreted in the culture medium of colon cancer
Author's personal copy
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Fig. 3. Expression on the surface and secretion in the culture medium of sLea
synthesized in different cell lines. Different cell lines were seeded at the same den-
sity, cultured for 48 h, harvested, and analyzed together with the culture media as
detailed under Section 2. (A) sLea antigen expressed on the cell surface (full bars) was
determined by immunostaining and ﬂow cytometry performed on a fresh aliquot of
the  cell pellet. 1,3Gal-T activity (empty bars) was  determined by in vitro assay as in
Fig. 1. Results are the mean ± standard deviation for three determinations. (B) sLea
secreted in the culture media was detected by immunostaining of dot-blots obtained
with 50 l of culture media, or quantitated by EIA. Numbers are the mean for three
determinations; standard deviations were less than 15%. (C) Correlation between
sLea measured on the surface (by ﬂow cytometry) and CA19.9 secreted in the cul-
ture media (quantitated by EIA) of colon cancer cell lines (HCT-15, CACO-2, HT-29,
differentiated CACO-2 and COLO-205). Input data were from panel B. Correlation
coefﬁcient is 0.998 as determined by linear regression.
cells (Fig. 3C), while those from pancreas or stomach seem to have
different behavior (Fig. 3C).
Noteworthy, 1,3Gal-T activity measured in CACO-2 and HT-
29 cells is 15.2 and 11.4 U, respectively. Such values, able to direct
only minimal secretion of antigen, are still 7- to 22-folds larger than
those measured in cancers patients 8 and 9 of Fig. 1A, whose serum
CA19.9 is indeed above the cut-off level.
3.3. Detection of sLea in the serum
Unfortunately, we lack serum samples from the same patients
where the biopsies are from. As an alternative, we checked sam-
ples from individuals whose serum levels of CA19.9 cover a wide
range. Fig. 4 shows that CA19.9 is very easily detected by dot-blot
immunostaining, even blotting minimal volumes of sera having low
antigen amounts measured by EIA. This indicates that the blotting
procedure is highly sensitive and that at least some immunogenic
properties of CA19.9 present in tissues, cells, and sera are simi-
lar. On the other side, the quantitative relationship between EIA
and blotting detection in cancer patient serum and in the bile is
Fig. 4. Detection of CA19.9 in patient serum and in the bile. The amounts of serum or
bile indicated were brought to the same volume, blotted, and stained with anti-sLea
antibody as in Fig. 1. EIA quantiﬁcation in the samples is shown at the top of the panel.
Numbers are the mean for three determinations; standard deviations were less than
15%. “A-F” are the serum samples indicated in the following lines: A is from a health
control, B, E, and F from cancer patients, C from a chronic alcoholic, and D from a
chronic C virus hepatitis patient. G is a bile sample, collected at cholecystectomy,
that  was diluted ten-times before blotting or assaying.
very poor, as found in the culture medium of BxPC3 cells. Such dis-
crepancy probably accounts for the structural heterogeneity of the
antigen, already proved to occur among different biological sources
but even within the same one (Baeckström et al., 1991, 1994, 1995;
Yue et al., 2011a, 2011b). At this regard, it is interesting to note that
CA19.9 circulating in the serum of cancer patients or present in the
bile is better detected by EIA than by blotting, while that found in
colon biopsies or colon-derived cell membranes and culture media
is not.
4. Discussion
We  found that the synthesis and secretion of CA19.9 antigen
in colon cancer presents several problems not supposed so far. In
fact we  found that 3Gal-T5, the enzyme responsible for one of the
glycosylation steps necessary for epitope synthesis, is so strongly
down-regulated in colon cancers that drops down to values far
below those needed to synthesize the antigen in cell lines. Further-
more, the antigen is not detectable in the cancer biopsies, or more
difﬁcult to detect than in the normal mucosa. Since in colon cancer
cell lines the amount of antigen secreted in the culture medium is
proportional to that expressed on the cell surface, our data open
the question if colon cancers are able to secrete large amounts of
sLea.
In previous studies, sLea was  found in some colon cancers ana-
lyzed by histochemistry (Ito et al., 1997; Kudo et al., 1998) or
sporadically distributed in some parts of the tumor (Tabuchi et al.,
1988), but western blot and histochemical data were not overlap-
ping (Kudo et al., 1998). On the light of our present data, we  suggest
that such discrepancies reﬂect the degree of blood contamination
in the tissues, or depend on binding to the cell membrane of the
antigen carried by the blood. In fact, we  found that patient serum is
very easily stained by anti-sLea antibody, so that 0.01 ml  of serum
seem to contain more sLea than some tens or even hundreds of
milligrams of colon cancer tissue. Moreover, studies performed on
colon cancer at surgery (Tabuchi et al., 1988; Nakagoe et al., 2000)
showed that CEA and sLex, but not CA19.9, are more elevated in
the blood from vessels draining the tumor region than in periph-
eral blood, with spikes coincident with surgery manipulation. Since
CEA (Maxwell, 1999) and sLex (Trinchera et al., 2011) are actually
synthesized by colon cancer cells, these in vivo results corrobo-
rate the data that we  obtained in cultured cell lines. It would be
very interesting in the future to validate such data in vivo com-
paring antigen levels in cancer biopsies and serum samples from
the same patient. At this stage, we speculate that the metabolic
origin of circulating CA19.9 should be searched in other tissues
actually able to synthesize and secrete relevant amounts of anti-
gen. Normal intestinal mucosa is a potential candidate, due to
the high expression levels of glycosyltransferases as 3Gal-T5 and
Author's personal copy
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Fuc-TIII. However, it does not accumulate large quantities of anti-
gen under basal conditions, probably because several additional
factors, unknown at present, control CA19.9 synthesis and secre-
tion in vivo, and any of them may  be triggered by the cancer
lesion. The biliary tract is also a candidate, because an amazing
huge amounts of CA19.9 (millions of U/ml) is present in the bile,
as reported (Baeckström et al., 1994) and conﬁrmed in our experi-
ments. However, a mechanism allowing CA19.9 elevation without
jaundice needs to be envisaged in this case. Anyway, our data are
compatible with the observation that appreciable levels of CA19.9
are commonly detected in healthy individuals (the source of which
remains totally unknown), and elevated levels, including extremely
high levels, occur in several benign conditions affecting the hepa-
tobiliary system (Mann et al., 2000; Akdog˘an et al., 2001; van der
Veek et al., 2011).
CA19.9 circulating in cancer patients was originally reported as
an high molecular weight mucin (size above 5.0 ×106 Da) (Magnani
et al., 1983), perhaps difﬁcult to immobilize on blotting mem-
branes. It is also predictable that such molecules bear several
epitopes all recognized by EIA but not by dot-blot immunostain-
ing. We  speculate that CA19.9 sources providing low-moderate
dot-blot staining but high titer by EIA, as the culture medium of
pancreatic BxPC3 cells, the bile, and the blood from some cancer
patients (E and F in Fig. 4), do contain a high molecular weight
form of the antigen, while the others do not. They include the cul-
ture medium from colon cancer cell lines and cell lysates from colon
cell lines and biopsies, where dot-blot immunostaining correlates
with EIA. Accordingly, the main molecules carrying CA19.9 in the
culture medium of COLO-205 cells were identiﬁed as CD-43 gly-
coforms (Baeckström et al., 1995), 150–300 kDa in size, expected
to easily bind blotting membranes. The molecular size heterogene-
ity of CA19.9 (Yue et al., 2011a)  may  be helpful in the future in
the attempt to identify the actual source of circulating antigen, an
information that we believe necessary to answer several clinical
questions.
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